A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
A single-arm, open, multicenter study to investigate the efficacy and safety of YY-20394, an
oral small molecular inhibitor of PI3K-delta, in patients with relapsed or refractory
peripheral T/NK cell lymphoma.